Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

Recruitment Underway for First in Human Study Investigating a Non-Hallucinogenic Psychoplastogen BOSTON, May 9, 2023 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the regulatory approval and initiation of recruitment of a phase I clinical trial of lead…


The product has been added to your cart.

Continue shopping View Cart